Dapagliflozin
Indication
Chronic kidney disease (NICE TA775)
NICE TA775 - Dapagliflozin for treating chronic kidney disease
Brand:
Nice TA:
775
Commissioning responsibility:
CCG
PbR excluded:
No
Background
1.1 Dapagliflozin is recommended as an option for treating chronic kidney disease (CKD) in adults. It is recommended only if:
-
it is an add-on to optimised standard care including the highest tolerated licensed dose of angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs), unless these are contraindicated, and
-
people have an estimated glomerular filtration rate (eGFR) of 25 ml/min/1.73 m2 to 75 ml/min/1.73 m2 at the start of treatment and:
-
have type 2 diabetes or
-
have a urine albumin-to-creatinine ratio (uACR) of 22.6 mg/mmol or more.
-
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care